Combining Optical Reporter Proteins with Different Half-lives to Detect Temporal Evolution of Hypoxia and Reoxygenation in Tumors

Pierre Danhier*, Balaji Krishnamachary*, Santosh Bharti*, Samata Kakkad*, Yelena Mironchik* and Zaver M. Bhujwalla*, †

*Division of Cancer Imaging Research, The Johns Hopkins University In Vivo Cellular and Molecular Imaging Center, The Russell H. Morgan Department of Radiology and Radiological Science, Baltimore, MD, USA; †Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract

Here we have developed a hypoxia response element driven imaging strategy that combined the hypoxia-driven expression of two optical reporters with different half-lives to detect temporal changes in hypoxia and hypoxia inducible factor (HIF) activity. For this purpose, human prostate cancer PC3 cells were transfected with the luciferase gene fused with an oxygen-dependent degradation domain (ODD-luc) and a variant of the enhanced green fluorescent protein (EGFP). Both ODD-luciferase and EGFP were under the promotion of a poly-hypoxia-response element sequence (5xHRE). The cells constitutively expressed tdTomato red fluorescent protein. For validating the imaging strategy, cells were incubated under hypoxia (1% O₂) for 48 hours and then reoxygenated. The luciferase activity of PC3-HRE-EGFP/HRE-ODD-luc/tdtomato cells detected by bioluminescent imaging rapidly decreased after reoxygenation, whereas EGFP levels in these cells remained stable for several hours. After in vitro validation, PC3-HRE-EGFP/HRE-ODD-luc/tdtomato tumors were implanted subcutaneously and orthotopically in nude male mice and imaged in vivo and ex vivo using optical imaging in proof-of-principle studies to demonstrate differences in optical patterns between EGFP expression and bioluminescence. This novel “timer” imaging strategy of combining the short-lived ODD-luciferase and the long-lived EGFP can provide a time frame of HRE activation in PC3 prostate cancer cells and will be useful to understand the temporal changes in hypoxia and HIF activity during cancer progression and following treatments including HIF targeting strategies.

Neoplasia (2015) 17, 871–881

Introduction

Hypoxia is frequently found in tumors and contributes to aggressiveness, resistance to treatment, and metastatic dissemination [1–4]. The adaptive response of cancer cells to hypoxia is mediated through the stabilization of hypoxia inducible factors (HIFs) that increases the transcription of several genes mediating this response by binding to hypoxia response elements (HREs) in the promoter region of these genes [5]. HIF is a heterodimeric basic helix-loop-helix PAS (Per-ARNT-Sim) domain containing transcription factor that consists of one of three oxygen-regulated α-subunits, HIF-1α, HIF-2α, and HIF-3α, and a constitutively expressed β-subunit (HIF-β/ARNT) [6,7]. The α-subunits are constitutively transcribed and translated, but are regulated at the protein level by oxygen-dependent hydroxylation of specific prolyl residues and degraded.
because of the presence of an oxygen-dependent degradation domain (ODD) [8]. The stabilization of HIF under hypoxia and its binding to the HRE provide a strategy to detect hypoxia by linking the HRE to the expression of optical reporter genes. Because increased HIF expression and stabilization can also occur under normoxia due to factors such as epi-/genetic HIF upregulation, PI3K-mTor pathway activation, and reactive oxygen species [9,10], such a strategy can also be used to detect HIF activity [11]. Tumor hypoxia evolves because of poor vascularization [9,10] but can resolve following increased angiogenesis and reoxygenation, making it important to track the dynamics of hypoxia and HIF activity in tumors.

Reporter genes that allow the visualization of molecular events in cells are widely used to track cells in vitro and in vivo when constitutively expressed [12–14]. Alternatively, these tools allow monitoring the activity of transcription factors such as HIF when specific promoters drive the expression of the reporter gene [15]. Among reporter genes, fluorescent proteins such as red and green fluorescent protein (RFP and GFP) are commonly used to study gene expression, protein trafficking, and cell localization in tissues [16]. In bioluminescence imaging (BLI), the firefly luciferase is the most commonly used reporter gene. In the presence of ATP and Mg++, luciferase catalyzes the oxidation of D-luciferin to oxyluciferin. This reaction also generates light (560 nm) [15,17]. Although the administration of D-luciferin is required, BLI is a sensitive imaging modality that allows monitoring cell migration, proliferation, and/or activation of signaling pathways in vivo [15,17].

The use of a destabilized variant of the enhanced green fluorescent protein (pd2EGFP) to characterize the relationship between hypoxia and vascularization in a PC3 prostate cancer xenograft model has been previously described [18–20]. The luciferase protein fused with ODD, under the promotion of five copies of HRE (5xHRE-ODD-luc), has also been previously used to monitor HIF-1 activity in xenograft tumors using BLI [11]. Addition of an ODD sequence strongly reduced the stability of the luciferase under normoxia, allowing dynamic monitoring of HIF-1 activity in vivo [11].

Here we have developed an imaging strategy based on the simultaneous HRE-driven expression of a long-lived EGFP and a short-lived luciferase fused to ODD in prostate cancer PC3 cells. Both reporter proteins were placed under the control of a 5xHRE sequence (schematic shown in Figure 1, A and B). PC3 cells also constitutively expressed tdTomato RFP to allow cell tracking (schematic shown in Figure 1B). This "timer" strategy can provide information on the temporal evolution of HIF activity and hypoxia in tumors. Because orthotopic tumor models better mimic clinical tumors compared with subcutaneous xenografts [21–23], we also performed in vivo and ex vivo imaging of the dual HIF reporter system (EGFP/ODD-luciferase) in PC3 tumors implanted subcutaneously and orthotopically in the prostate and observed patterns of EGFP and BLI colocalization as well as regions with low overlap in subcutaneous and orthotopic tumors and metastatic nodules.

**Material and Methods**

**Generation of the 5xHRE-ODD-luc Construct with a Puromycin Selection Marker**

To construct the plasmid encoding the luciferase gene fused to ODD under the control of a poly-HRE sequence (5xHRE) with a puromycin resistance cassette, the 5xHRE-ODD-luc (firefly luciferase
fused with ODD) sequence from a 5HREp-ODD-luc plasmid (kindly provided by Dr. H. Harada) was digested with restriction enzymes Kpn1 and XbaI (NEB, Ipswich, MA) and subcloned between Kpn1 and EcoRI of a pGL4.21 [luc2P/Puro] (Promega, Madison, WI) vector.

**Generation of the PC3-HRE-EGFP/HRE-ODD-luc/tdTomato Cell Line**

Human prostate cancer PC3 cells and PC3 cells expressing the enhanced green fluorescent protein variant pd2EGFP under the promotion of a 5xHRE sequence (PC3-HRE-EGFP) were transfected with the 5xHRE-ODD-luc construct (PC3-HRE-ODD-luc and PC3-HRE-EGFP/HRE-ODD-luc) using jetPRIME reagent (Polyplus transfection Inc., New York, NY) following the manufacturer’s protocol. Transfected cells were next selected using 1 μg/ml of puromycin.

PC3-HRE-EGFP/HRE-ODD-luc cells constitutively expressing the bright RFP tdTomato (PC3-HRE-EGFP/HRE-ODD-luc/tdTomato) were generated by lentiviral infection with the pRRLΔluc construct (Promega) following manufacturer’s instructions. Luciferase activity measurements were performed using a Victor 3V plate reader (Perkin Elmer, Waltham, MA).

**Western Blots**

Whole cell extracts from 80% to 90% confluent 10-mm dishes were prepared in radioimmune precipitation buffer, fractionated by SDS-PAGE, transferred to a nitrocellulose membrane, and subjected to immunoblot assays using a monoclonal anti-EGFP, mouse antibody (dilution 1:2000, BD Biosciences, San Jose, CA), an anti-HIF-1α antibody (dilution 1:1000, Novus Biologicals, Denver, CO), and a monoclonal anti-actin mouse antibody (dilution 1:50000, Sigma, St. Louis, MO). Horseradish peroxidase-conjugated secondary antibody against either mouse or rabbit IgG was used at 1:2000 dilutions. The signal was visualized using ECL Plus reagents (Thermo Scientific, Rockford, IL). For experiments involving cycloheximide (CHX, Sigma), an inhibitor of protein synthesis, cell extracts from 103 cells were loaded per lane. Otherwise, protein quantification was performed before sample loading. CHX toxicity was assessed using the trypan blue exclusion test.

**Cell Culture and Hypoxia Treatment**

PC3 cells were grown in RPMI medium with L-glutamine supplemented with 10% (v/v) fetal bovine serum. PC3-HRE-EGFP cells were supplemented with 400 μg/ml of G418, PC3-HRE-ODD-luc cells were supplemented with 1 μg/ml of puromycin, and PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells were supplemented with both 400 μg/ml of G418 and 1 μg/ml of puromycin.

Hypoxic treatment of cells was performed either by placing the plates in a modular incubator chamber (Billups-Rothenberg, Del Mar, CA), flushed at 2 psi for 3 minutes with a gas mixture of 1% O2/5% CO2, and N2 for the balance, or by treating cells with Mar, CA), flushed at 2 psi for 3 minutes with a gas mixture of 1%

**Fluorescence Imaging**

For fluorescence quantification experiments, PC3-HRE-EGFP and PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells were seeded at low density in six-well plates and allowed to grow for 2 weeks. The resulting cell colonies were incubated at 1% O2 for 48 hours and imaged after reoxytgenation using a Nikon inverted microscope equipped with a Nikon Coolpix digital camera (Nikon Instruments, Inc., Melville, NY) at 20× magnification. Exposure times were kept constant during time-lapse imaging experiments. For EGFP imaging, background signal was subtracted using the rolling ball algorithm from ImageJ software (NIH), and brightness was adjusted. All image corrections were kept similar within experiments. For fluorescence quantification, regions of interest were manually drawn for each cell, and fluorescence quantification was performed using the following formula [24]:

\[
\text{Cell fluorescence intensity} = \frac{\text{sum of cell pixel intensities} - \text{(mean background intensity} \times \text{cell area)}}{\text{cell area}}
\]

**Luciferase Activity Measurements**

PC3-HRE-ODD-luc and PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells grown at 80% to 90% confluence in 6-well plates were washed with PBS and lysed in Cell Culture Lysis Reagent (Promega) at various time points after hypoxia treatments. The luciferase activity was measured in cell lysates using Luciferase Assay Systems (Promega) following manufacturer’s instructions. Luciferase activity measurements were performed using a Victor 3V plate reader (Perkin Elmer, Waltham, MA).

**Animal Studies**

All experimental animal protocols were approved by the Institutional Animal Care and Use Committee of the Johns Hopkins University School of Medicine. Animal studies were performed on adult nude male mice inoculated subcutaneously with 2 × 106 million cancer cells. For orthotopic implantation, a 1-mm3 piece of tumor tissue was microsurgically sutured into the prostate gland through a small incision as previously described [20]. Tumor pieces were obtained from a subcutaneous tumor and carefully dissected under a fluorescence microscope to remove hypoxic and necrotic tissue. Subcutaneous and orthotopic tumor volumes were approximately 400 to 500 mm3 at the time of imaging.

**Optical Imaging**

Optical imaging was performed using a Xenogen IVIS Spectrum system (Caliper Life Sciences, Hopkinton, MA). EGFP was detected using an excitation light of 500 nm and an emission filter set at 540 nm. tdTomato was detected using an excitation light of 570 nm and an emission filter set at 620 nm. For in vitro bioluminescence experiments, D-luciferin (150 μg/ml) (Promega) was added to samples before imaging. For in vivo BLI experiments, D-luciferin dissolved in PBS was injected intraperitoneally (3 mg/mouse) 15 minutes before imaging. Exposure times were kept constant within experiments. End point fluorescence and bioluminescence imaging of fresh 2-mm-thick tumor slices prepared with a tissue slicer was performed with the Xenogen system or using a 1× objective on a fluorescence microscope (Nikon Ltd., Melville, NY). Fluorescence and bioluminescence quantification was performed on manually drawn regions of interest using the Living Image software (Perkin Elmer). The average radiant efficiency [(photons/s per cm2 per sr)/(μW/cm2)] was determined for fluorescence images, and the average radiance (photons/s per cm2 per sr) was measured for bioluminescence images.

**Statistical Analyses**

All results are represented as means ± SEM. Comparisons between groups were performed using Student’s t test when two groups were compared. One-way analysis of variance followed by Tukey’s multiple comparison tests was used when more than two groups were compared. P < .05 was considered to be statistically significant.
significant. Statistical analyses, and EGFP and ODD-luciferase protein half-lives were determined using the GraphPad Prism software (La Jolla, CA).

Results

EGFP Is More Stable than ODD-luc in PC3-HRE-EGFP/HRE-ODD-luc/tdTomato Cells Following Reoxygenation

To characterize the stability of EGFP, PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells were incubated under hypoxia (48 hours at 1% O₂) and then reoxygenated. As shown in Figure 2, bright green fluorescence was observed in cell colonies immediately after the hypoxia was released. The green fluorescence remained stable for 4 hours and then progressively started to decrease to undetectable levels within 24 hours after reoxygenation (Figure 2). The same experiment was repeated with cells treated with CHX after hypoxia to inhibit de novo protein synthesis. With CHX (100 μg/ml), EGFP fluorescence intensity was detected 4 hours after reoxygenation but was barely detectable 8 hours after reoxygenation (Figure 2). The EGFP degradation half-life was approximately 15 hours without CHX treatment and approximately 83 minutes in CHX-treated cells. In both control and CHX-treated cells, tdTomato fluorescence intensity was initially dim and progressively increased to become stable 4 hours after reoxygenation (Figure 2). The decrease in tdTomato fluorescence was observed when cells were incubated at 1% O₂ but not when treated with 200 μM of CoCl₂ for 24 hours (Figure S1). To confirm microscopy results, the stability of EGFP after reoxygenation was also characterized in immunoblots. As shown in Figure 3A, EGFP protein levels remained stable for 8 hours in cells without CHX after reoxygenation. On the other hand, EGFP protein levels decreased progressively in CHX-treated cells but remained detectable up to 6 hours after reoxygenation. CHX was found to be nontoxic in PC3 cells, and cell numbers remained stable after CHX addition (Figure S2).

We next examined the stability of the luciferase protein fused with ODD in PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells after a 48-hour incubation at 1% O₂. Figure 3B shows that the luciferase activity quickly decreased after reoxygenation. After 4 hours of reoxygenation, the luciferase activity was 24.85 ± 4.81% of its original value in control cells and 8.80 ± 0.8% in CHX-treated cells (Figure 3B). The ODD-luciferase half-life was approximately 34 minutes in control cells without CHX treatment and approximately 11 minutes in CHX-treated cells.

The stability of EGFP and ODD-luc after reoxygenation was also characterized in PC3 cells carrying either the 5xHRE-EGFP construct (PC3-HRE-EGFP) or the 5xHRE-ODD-luc construct (PC3-HRE-ODD-luc). Briefly, the stability of both reporters was found to be similar in PC3-HRE-EGFP and PC3-HRE-ODD-luc cells compared with PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells (Figure S3).
A strong EFGP induction was observed after a 24-hour incubation at 1% O₂. However, EGFP expression could only be detected after 8 hours of hypoxia, and a 24-hour incubation at 1% O₂ was sufficient to stabilize HIF-1 α. As shown in Figure 4, a marked increase in the luciferase activity was observed in cells reoxygenated for 4 hours after 8-, 24-, and 48-hour incubation at 1% O₂ in comparison with hypoxic groups (Figure 5).

**Optical Imaging Allows HIF-1 Imaging in PC3-HRE-GFP/HRE-ODD-luc/tdTomato Cells**

Using optical imaging, we next aimed to image simultaneously EGFP, tdTomato, and bioluminescence produced by PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells. For these experiments, microtubes containing CoCl₂-treated (200 μM for 24 hours) or normoxic cell pellets (3×10⁶ cells/tube) were imaged. As shown in Figure 6, a marked increase in the EGFP signal was observed in PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells treated with CoCl₂, whereas only a background autofluorescence signal was measured in normoxic cells. Similar levels of tdTomato signal intensity were detected in both normoxic and CoCl₂-treated cells (Figure 6). A BLI signal was detected in normoxic PC3-HRE-GFP/HRE-ODD-luc/tdTomato cells but not in normoxic cells reoxygenated for 4 hours after reoxygenation (Figure 7).

**The Combination of Long-Lived EGFP and Short-Lived ODD-Luciferase Allows Differentiation between Normoxic, Hypoxic, and Reoxygenated PC3 Cells Using Optical Imaging**

Taking advantage of the different stabilities of EGFP and ODD-luc proteins, we next aimed to visualize normoxic, hypoxic, and reoxygenated PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells using optical imaging. As shown in the representative images in Figure 7A and quantified intensities in Figure 7B, BLI activity was detected in hypoxic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells but not in normoxic cells. After 4 hours of reoxygenation, the BLI signal significantly dropped in these cells (Figure 7, A and B). Representative EGFP images shown in Figure 7A and quantified intensities in Figure 7B demonstrate the significant increase of signal from hypoxic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells compared with normoxic cells. Consistent with its long-lived feature and unlike the pattern from short-lived luciferase, the EGFP fluorescence was not statistically different in hypoxic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells compared with reoxygenated cells (Figure 7, A and B). However, a decrease in tdTomato fluorescence was observed in hypoxic PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells in comparison with normoxic and reoxygenated cells (Figure 7, A and B). As shown in the representative immunoblot in Figure 7C, HIF-1 α was stabilized in PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells after 48 hours at 1% O₂ but not 4 hours after reoxygenation. EGFP protein levels were found to increase after a 48-hour hypoxia treatment and were sustained at 4 hours after reoxygenation (Figure 7C).

**The "Timer" Imaging Method Based on the 5xHRE-EGFP and 5xHRE-ODD-luc Constructs Allows the Dynamic Visualization of HIF-1 Activation in PC3 Prostate Tumors**

In proof-of-principle studies, PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells were inoculated subcutaneously in a group of mice to determine if differences in expression patterns of luciferase and EGFP were detected. As shown in the representative images, tumors where high intensity of BLI and EGFP regions colocalized were...
frequently observed (Figure 8A), which was confirmed in ex vivo tissue slices (Figure 8B). We also observed patterns in some tumors where high-intensity regions of BLI and EGFP did not colocalize, which was confirmed in the ex vivo tissue slices and indicated differences in the temporal evolution or resolution of HIF activity and hypoxia.

We additionally performed in vivo and ex vivo imaging of the dual HIF reporter system (EGFP/ODD-luciferase) in PC3 tumors implanted in the prostate. Representative in vivo images are presented in Figure 8C. Hypoxic tumor areas were not evident in the primary tumor, but both EGFP and BLI were observed in a peritoneal metastatic lesion.

![Figure 4](image)

**Figure 4.** Expression and stability of EGFP following different hypoxia-reoxygenation treatments in PC3-HRE-GFP/HRE-ODD-luc/tdTomato cells. (A) Representative Western blot showing HIF-1α and EGFP protein expression in PC3-HRE-GFP/HRE-ODD-luc/tdTomato cells incubated under normoxia, or under hypoxic conditions for 4, 8, 24, or 48 hours. For each hypoxic treatment, cells were immediately collected for Western blot analysis (−) or reoxygenated for 4 hours (+). (B) Representative images of EGFP and tdTomato fluorescence of PC3-HRE-GFP/HRE-ODD-luc/tdTomato cells following hypoxic treatments and reoxygenation for 4 hours.

![Figure 5](image)

**Figure 5.** Luciferase activity of PC3-HRE-GFP/HRE-ODD-luc/tdTomato cells following different hypoxia-reoxygenation treatments. PC3-HRE-GFP/HRE-ODD-luc/tdTomato cells were submitted to hypoxia treatments for 4, 8, 24, or 48 hours and immediately collected for luciferase assays (−) or reoxygenated for 4 hours (+) \((n = 3)\). Data are expressed as mean ± SEM. \(*P < .05; **P < .01; ***P < .001; not significant (ns), P > .05.\)
Here we have described an imaging strategy to determine the history of HIF activation in prostate cancer cells. The use of a “timer” reporter protein was first described in 2000 by Terskikh et al.[25]. The fluorescence of this timer, named E5, changed from green to red in a time-dependent manner after expression[25]. More recently, the simultaneous use of two fluorescent proteins with different maturation half-lives (fusion proteins or bicistronic expression) was described for monitoring the temporal changes of the activity of a given reporter[26–28]. Here, we have developed a timer strategy based on the combination of two reporter genes, regulated by an HIF-dependent promoter, with different degradation half-lives. Using optical imaging, we demonstrated that the combination of a long-lived EGFP and a short-lived luciferase fused to ODD allowed the identification of normoxic (EGFP−/luc−), hypoxic (EGFP+/luc+), and reoxygenated (EGFP+/luc−) prostate cancer cells. No cross talk between reporter proteins was observed during the multiplex imaging of EGFP, tdTomato, and bioluminescence in PC3 cells following a hypoxia challenge. The EGFP degradation half-life values of 15 hours without CHX treatment and approximately 83 minutes with CHX treatment are comparable to previously published values[29], as are the ODD-luciferase half-life values of approximately 34 minutes without CHX treatment and approximately 11 minutes in CHX-treated cells[11]. CHX treatment resulted in a steeper decline of luciferase activity and EGFP protein compared with untreated cells undergoing reoxygenation. This may be, in part, because the oxygen tensions may have taken longer to equilibrate and recover to normoxic levels during the reoxygenation process.

In the tumors, we observed colocalized regions of high BLI and high EGFP, as well as regions that did not colocalize. Regions with high BLI but low EGFP may represent early hypoxia, regions with high BLI and EGFP may represent long-term hypoxia, and regions with low BLI and high EGFP may represent reoxygenated regions that were previously hypoxic. Because the reporters are being expressed following HIF stabilization, it is also important to consider other mechanisms that may induce HIF stabilization in vivo such as reactive oxygen species that can be upregulated in tumors because of high oxidative stress[10,30]. HIF stabilization due to oxidative stress may, however, result in a more uniform expression of the reporters unlike the distinct localized regions we observed in tumors in this study.

We previously observed that lymph node metastases arising from PC3-HRE-EGFP orthotopic tumors emitted green fluorescence, indicating the presence of hypoxic areas in metastases[20]. Here, following tumor implantation in the orthotopic site that is permissive to metastatic dissemination, we found no detectable hypoxia in the primary but both EGFP and BLI in a peritoneal metastasis. Based on the expression patterns of luciferase and EGFP, the “timer” strategy described here could be used to determine whether metastatic prostate cancer cells in the lymph nodes become hypoxic at the metastatic site or were already hypoxic in the primary tumor. Although serially imaging the luciferase reporter alone would detect the presence of hypoxia, this would not provide a longer-term history of whether hypoxia existed before reoxygenation in regions where there is no luciferase activity. This information is important to characterize the role of hypoxic environments in the primary tumor in the metastatic process.

The fluorescence of the constitutive tdTomato protein, used for cell tracking, was found to decrease at 1% O2 but remained constant after incubation with CoCl2. This can be explained by the fact that an oxidation step requiring O2 is needed in the maturation process of fluorescent proteins to produce light. Differences in maturation rates or oxygen requirements between fluorescent proteins may explain why such a phenomenon was more pronounced with tdTomato compared with EGFP[31,32]. In another study, pd2EGFP fluorescence decreased but only at near-anoxic conditions (<0.06% O2)[33]. The authors concluded that EGFP was a suitable reporter gene for monitoring tumor
hypoxia [33]. Although oxygen and ATP are required for the generation of light by luciferase proteins, Harada et al. [11] have observed that the BLI signal coming from xenograft HeLa-HRE-ODD-luc tumors implanted in the mouse leg increased after ligation, consistent with the increased BLI signal of the HRE-ODD-luc construct in response to hypoxia observed in our study. In a separate study, the BLI signal from luciferase-positive 9L gliosarcoma cells was measured at various percentages of O2 [34]. Only small differences were found in cells exposed to 5% compared with 0.2% O2 [34], suggesting that ATP, rather than oxygen levels, affected the luciferase activity in these cells [34]. Sustained anoxia, on the other hand, will result in cell death and the absence of both EGFP and BLI signal.

Tumor hypoxia is a poor prognosticator that is associated with chemo- and radioresistance and recurrence [35,36]. As a result, HIF targeting strategies are being evaluated in clinical trials (Clinical-Trials.gov identifier: NCT01111097). Briefly, chronic hypoxia results from the limited diffusion of oxygen to tumor cells distant from blood vessels [35], and acute hypoxia can result from vascular collapse due to increased tumor interstitial pressure [35]. The formation of hypoxia results in the upregulation of vascular endothelial growth factor [37] that can lead to increased angiogenesis and neovascularization and reoxygenation of hypoxic regions. Reoxygenation also occurs during therapy when cell death provides increased nutrients and oxygen to the remaining cells [38,39]. Cycling hypoxia due to variations of red blood cell flux in tumor vessels has also been observed in tumors [40]. Endothelial cancer cells submitted to cycling hypoxia had increased levels of HIF-1 induction compared with cancer cells submitted to chronic hypoxia. This phenomenon was associated with an increased survival of cancer cells after radiotherapy in vivo [41].

---

**Figure 7.** Optical imaging of long-lived EGFP and short-lived ODD-luciferase in normoxic, hypoxic, and reoxygenated PC3-HRE-GFP/HRE-ODD-luc/tdTomato cells. (A) Representative optical images of PC3-HRE-GFP/HRE-ODD-luc/tdTomato pellets (3 × 10^6 cells/tube). EGFP is displayed in red. Cells were exposed to normoxia, 48 hours 1% O2, or 48 hours 1% O2 followed by 4-hour reoxygenation. (B) Quantification of EGFP, tdTomato, and BLI quantification of images acquired with the optical imaging scanner (n = 3 per group). (C) Representative immunoblots of PC3-HRE-GFP/HRE-ODD-luc/tdTomato cell lysates showing HIF-1α and EGFP protein levels under normoxia (N), 48 hours 1% O2, or 48 hours 1% O2 followed by 4-hour reoxygenation. Data are expressed as mean ± SEM. *P < .05; **P < .01; ***P < .001; ns, P > .05.
Figure 8. Optical imaging patterns of two representative subcutaneous and orthotopic PC3-HRE-GFP/HRE-ODD-luc/tdTomato tumors together with a metastatic lesion. (A) Representative *in vivo* images of EGFP and tdTomato fluorescence and bioluminescence of mice with subcutaneous tumors. (B) Colocalization and mismatch between BLI and EGFP distributions in 2-mm–thick central tumor slice from each tumor in (A) imaged *ex vivo* using a Xenogen IVIS Spectrum imager and fluorescence microscopy. The scale bar represents 2 mm. (C) Representative *in vivo* images of EGFP and tdTomato fluorescence and bioluminescence of a mouse with a primary orthotopic tumor (P) and a peritoneal metastatic lesion (M). No EGFP or BLI is detected in the primary tumor unlike the metastatic lesion that shows both EGFP and BLI.
Cycling hypoxia was found to result from both fast fluctuations of oxygenation (several cycles/hour) and slow fluctuations of oxygenation (over many hours and days). It was hypothesized that low-frequency variations in oxygen pressure in tumors could be due to vascular remodeling following angiogenesis [42,43]. We observed that a 24-hour incubation of PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells at 1% O₂ was required to detect EGFP using fluorescence microscopy. Our results also showed that the luciferase activity of PC3-HRE-EGFP/HRE-ODD-luc/tdTomato cells quickly dropped after reoxygenation, whereas EGFP levels remained stable for several hours. The dual EGFP/ODD-luciferase reporter system may be used to detect reoxygenation processes due to angiogenesis after long periods of hypoxia. Alternatively, the “timer” HIF imaging strategy can detect rapid variations of O₂ after sustained hypoxia. The characterization of HIF inhibitors and radiosensitizing drugs that alleviate tumor hypoxia is another promising field of application for such an HIF imaging method [1,43–45].

One limitation of the reporter system developed here arises from different sensing depths between EGFP and BLI. Unlike BLI, fluorescence from EGFP is affected by tissue attenuation during excitation and emission. As a result, in vivo variations in tissue thickness will play a role in the EGFP intensities that are detected. Unlike the in vivo data, because the ex vivo slices are of uniform thickness and only 2 mm thick, light attenuation may not be significant enough to pose a problem when comparing EGFP and BLI intensity distribution. Although the ex vivo slice data are ‘snapshots’ and do not allow longitudinal studies, they still provide temporal insights into HIF and hypoxia patterns in the tumor and in metastatic lesions. In addition, it was not possible to perform single cell imaging using our current in vivo optical imaging system, although fluorescence imaging of isolated cells tagged with fluorescent reporter proteins has been reported in vivo using intravital microscopy [46–48].

In conclusion, this novel “timer” imaging strategy of combining the short-lived ODD-luciferase and the long-lived EGFP has the potential to advance our understanding of temporal changes in hypoxia and HIF in the primary tumor and during the metastatic cascade, and for understanding therapy-based changes in tumor HIF expression, especially for treatments that target the HIF pathway.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.neo.2015.11.007.

Acknowledgements
P. Danhier was supported by the Belgian American Educational Foundation (BAEF) and by the Fonds Spécialis de la Recherche (Université catholique de Louvain). This work was supported by National Institutes of Health R01 CA73850, R01 CA82337, and P50 CA103175. We thank Dr. Marie-France Penet for assistance with the tumor studies and Dr. Venu Raman for originally developing the PC-3 HRE EGFP cells.

References
[1] Gilkes DM and Semenza GL (2013). Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol 9, 1623–1636.
[2] Penet MF, Chen Z, and Bhujwalla ZM (2011). MRI of metastasis-permissive microenvironments. Future Oncol 7, 1269–1284.
[3] Semenza GL (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625–634.
[4] Gilkes DM, Semenza GL, and Wirtz D (2014). Hypoxia and the extracellular matrix: drivers of tumour metastasis. Nat Rev Cancer 14, 430–439.
[5] Fraga A, Ribeiro R, Principe P, Lopes C, and Medeiros R (2015). Hypoxia and Prostate Cancer Aggressiveness: A Tale With Many Endings. Clin Genitourin Cancer 13, 295–301.
[6] Hu C, Saurat A, Wang L, Chen H, and Simon MC (2007). The N-terminal transactivation domain contains target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol Biol Cell 18, 4528–4542.
[7] Tian H, McKnight SL, and Russell DW (1997). Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 11, 72–82.
[8] Berchner-Pfannschmidt U, Frede S, Wozlaw C, and Fandrey J (2008). Imaging of the hypoxia-inducible factor pathway: insights into oxygen sensing. Eur Respir J 32, 210–217.
[9] Ranasinghe WK, Baldwin GS, Bolton D, Shulkes A, Ischia J, and Patel O (2015). HIF-1α expression under normoxia in prostate cancer–which pathways to target? J Urol 193, 763–770.
[10] Krock BL, Skuli N, and Simon MC (2011). Hypoxia-induced angiogenesis: good and evil. Genes Cancer 2, 1117–1153.
[11] Harada H, Kizaka-Kondoh S, Itohara S, Shibuya K, Morinobu A, Shinomiya K, and Hiraoka M (2007). The combination of hypoxia-response enhancers and an oxygen-dependent proteolytic motif enables real-time imaging of absolute HIF-1 activity in tumor xenografts. Biochem Biophys Res Commun 360, 791–796.
[12] Winnard Jr PT, Kluth JB, and Raman V (2006). Noninvasive optical tracking of red fluorescent protein-expressing cancer cells in a model of metastatic breast cancer. Neoplasia 8, 796–806.
[13] O’Farrell AC, Shnyder SD, Marston G, Coletta PL, and Gill JH (2013). Non-invasive molecular imaging for preclinical cancer therapeutic development. Br J Pharmacol 169, 719–735.
[14] Danhier P, De Preter G, Magat J, Godechal Q, Porporato PE, Jordan BF, Feron O, Sonveaux P, and Gallez B (2014). Multimodal cell tracking of a spontaneous metastasis model: comparison between MRI, electron paramagnetic resonance and bioluminescence. Contrast Media Mol Imaging 9, 143–153.
[15] Brogan J, Li F, Li W, He Z, Huang Q, and Li CY (2012). Imaging molecular pathways: reporter genes. Radiat Res 177, 508–513.
[16] Chudakov DM, Matz MV, Lukyanov S, and Lukyanov KA (2010). Fluorescent proteins and their applications in imaging living cells and tissues. Physiol Rev 90, 1103–1163.
[17] de Almeida PE, van Rappard Jr, and Wu JC (2011). In vivo bioluminescence for tracking cell fate and function. Am J Physiol Heart Circ Physiol 301, H663–671.
[18] Raman V, Artemov D, Pathak AP, Winnard Jr PT, McNutt S, Yudina A, Bogdanov Jr A, and Bhujwalla ZM (2006). Characterizing vascular parameters in hypoxic regions: a combined magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res 66, 9929–9936.
[19] Glunde K, Shah T, Winnard Jr PT, Raman V, Talaqi T, Vesuna F, Artemov D, and Bhujwalla ZM (2008). Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res 68, 172–180.
[20] Penet MF, Pathak AP, Raman V, Ballesteros P, Artemov D, and Bhujwalla ZM (2009). Noninvasive multiparametric imaging of metastasis-permissive microenvironments in a human prostate cancer xenograft. Cancer Res 69, 8822–8829.
[21] Yang M, Jiang P, Yamamoto N, Li L, Geller J, Moossa AR, and Wu ZX (2010). A novel contrast agent for monitoring intracellular pH in living cells. Invest New Drugs 28, 263–274.
[22] Penet MF, Pathak AP, Raman V, Ballesteros P, Artemov D, and Bhujwalla ZM (2009). HIF1alpha expression under normoxia in prostate cancer xenografts. Biochem Biophys Res Commun 395, 82–86.
[23] Hoffmann RM (2005). Real-time whole-body imaging of an orthotopic metastatic prostate cancer model expressing red fluorescent protein. Prostate 62, 374–379.
[24] Hoffmann RM (2015). Patient-derived orthotopic xenografts: better mimic of metastasis than subcutaneous xenografts. Nat Rev Cancer 15, 451–452.
[25] Hoffmann RM (1999). Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17, 343–359.
[26] Gavet O and Pines J (2010). Progressive activation of CyclinB1-Cdk1 coordinates entry to mitosis. Dev Cell 18, 533–543.
[27] Terskikh A, Fradkov A, Ermakova G, Zaraisky A, Tan P, Kajava AV, Zhao X, Lukyanov S, Marz M, and Kim S, et al (2000). “Fluorescent timer” : protein that changes color with time. Science 290, 1585–1588.
[28] Chen MR, Yang S, Niu WP, Li ZY, Meng LF, and Wu ZX (2010). A novel fluorescent timer based on bistronic expression strategy in Caenorhabditis elegans. Biochem Biophys Res Commun 395, 82–86.
[29] Dona E, Barry JD, Valentin G, Quirin C, Khmelinskii A, Kunze A, Durdu S, Newton LR, Fernandez-Minan A, and Huber W, et al (2013). Directional tissue migration through a self-generated chemokine gradient. Nature 503, 285–289.
[30] Khmelinskii A, Keller PJ, Bartosik A, Meurer M, Barry JD, Mardin BR, Kaufmann A, Trautmann S, Wachsman M, and Pereira G, et al (2012),
Tandem fluorescent protein timers for in vivo analysis of protein dynamics. Nat Biotechnol 30, 708–714.

[29] Tryfonidou MA, Lunstrum GP, Hendriks K, Riemers FM, Wubbolts R, Hazewinkel HA, Degnin CR, and Horton WA (2011). Novel type II collagen reporter mice: New tool for assessing collagen 2alpha1 expression in vivo and in vitro. Dev Dyn 240, 663–673.

[30] Li F, Sonveaux P, Rabbani ZN, Liu S, Yan B, Huang Q, Vujaskovic Z, Dewhirst MW, and Li CY (2007). Regulation of HIF-1alpha stability through S-nitrosylation. Mol Cell 26, 63–74.

[31] Macdonald PJ, Chen Y, and Mueller JD (2012). Chromophore maturation and fluorescence fluctuation spectroscopy of fluorescent proteins in a cell-free expression system. Anal Biochem 421, 291–298.

[32] Shaner NC, Steinbach PA, and Tsien RY (2005). A guide to choosing fluorescent proteins. Nat Methods 2, 905–909.

[33] Vordermark D, Shibata T, and Brown JM (2001). Green fluorescent protein is a suitable reporter of tumor hypoxia despite an oxygen requirement for chromophore formation. Neoplasia 3, 527–534.

[34] Moriyama EH, Niedre MJ, Jarvi MT, Mocanu JD, Moriyama Y, Subarsky P, Li B, Lilge LD, and Wilson BC (2008). The influence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro. Photochem Photobiol Sci 7, 675–680.

[35] Horsman MR, Mortensen LS, Petersen JB, Busk M, and Overgaard J (2012). Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9, 674–687.

[36] Rohwer N and Cramer T (2011). Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 14, 191–201.

[37] Unwith S, Zhao H, Hennah L, and Ma D (2015). The potential role of HIF on tumour progression and dissemination. Int J Cancer 136, 2491–2503.

[38] Vaupel P, Kelleher DK, and Thews O (1998). Modulation of tumor oxygenation. Int J Radiat Oncol Biol Phys 42, 843–848.

[39] Danhier F, Danhier P, Magotteaux N, De Preter G, Ucakar B, Karroum O, Jordan B, Gallez B, and Preat V (2012). Electron paramagnetic resonance highlights that the oxygen effect contributes to the radiosensitizing effect of paclitaxel. PLoS One 7, e40772.

[40] Lee CT, Boss MK, and Dewhirst MW (2014). Imaging tumor hypoxia to advance radiation oncology. Antioxid Redox Signal 21, 313–337.

[41] Martinive P, Defresne F, Bouzin C, Saliez J, Lair F, Gregoire V, Michiels C, Desy C, and Feron O (2006). Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66, 11736–11744.

[42] Dewhirst MW (2009). Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res 172, 653–665.

[43] Danhier P, De Saedeleer CJ, Karroum O, De Preter G, Porporato PE, Jordan BF, Gallez B, and Sonveaux P (2013). Optimization of tumor radiotherapy with modulators of cell metabolism: toward clinical applications. Semin Radiat Oncol 23, 262–272.

[44] Samanta D, Gilkes DM, Chaturvedi P, Xiang L, and Semenza GL (2014). Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci U S A 111, 5429–5438.

[45] Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3, 721–732.

[46] Hoffman RM and Yang M (2006). Subcellular imaging in the live mouse. Nat Protoc 1, 775–782.

[47] Hoffman RM and Yang M (2006). Color-coded fluorescence imaging of tumor-host interactions. Nat Protoc 1, 928–935.

[48] Hoffman RM (2005). The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat Rev Cancer 5, 796–806.